Compare MCK & APO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCK | APO |
|---|---|---|
| Founded | 1833 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.4B | 84.9B |
| IPO Year | N/A | 2011 |
| Metric | MCK | APO |
|---|---|---|
| Price | $819.05 | $146.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $882.69 | $165.17 |
| AVG Volume (30 Days) | 868.8K | ★ 3.2M |
| Earning Date | 02-04-2026 | 02-03-2026 |
| Dividend Yield | 0.40% | ★ 1.39% |
| EPS Growth | ★ 66.19 | N/A |
| EPS | ★ 32.12 | 6.87 |
| Revenue | ★ $387,094,000,000.00 | $27,217,000,000.00 |
| Revenue This Year | $14.87 | N/A |
| Revenue Next Year | $8.32 | $41.26 |
| P/E Ratio | $25.54 | ★ $21.31 |
| Revenue Growth | ★ 17.23 | N/A |
| 52 Week Low | $565.75 | $102.58 |
| 52 Week High | $895.58 | $175.08 |
| Indicator | MCK | APO |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 67.35 |
| Support Level | $801.21 | $145.56 |
| Resistance Level | $824.95 | $150.63 |
| Average True Range (ATR) | 16.74 | 3.83 |
| MACD | -2.27 | 0.52 |
| Stochastic Oscillator | 45.20 | 74.72 |
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Apollo is one of the world's largest alternative asset managers, with $908.4 billion in total assets under management, or AUM, including $685.0 billion in fee-earning assets, at the end of September 2025. The company has two core operating segments: asset management and retirement services. Apollo operates with scale in each of its major product lines—private equity (with $125.6 billion in total AUM and $71.7 billion in fee-earning AUM), real estate/real assets ($59.6 billion/$27.1 billion), and private credit ($723.2 billion/$586.2 billion). Apollo has a distribution profile that is likely not too far off from the industry averages—with 84% of its assets held by institutional investors and 16% by high-net-worth clients.